What is Zacks Research’s Forecast for LEXX FY2026 Earnings?

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Equities researchers at Zacks Research decreased their FY2026 earnings per share estimates for shares of Lexaria Bioscience in a report released on Friday, July 17th. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings of ($0.27) per share for the year, down from their previous forecast of ($0.26). The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.27) per share.

Lexaria Bioscience (NASDAQ:LEXX) last announced its quarterly earnings data on Monday, July 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02).

Separately, Weiss Ratings raised shares of Lexaria Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $1.50.

Lexaria Bioscience Stock Performance

Shares of Lexaria Bioscience stock opened at $0.57 on Thursday. The company has a 50-day simple moving average of $0.59 and a two-hundred day simple moving average of $0.71. The stock has a market capitalization of $14.14 million, a PE ratio of -1.68 and a beta of 0.34. Lexaria Bioscience has a 52-week low of $0.46 and a 52-week high of $1.55.

Institutional Investors Weigh In On Lexaria Bioscience

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in Lexaria Bioscience by 25.7% during the 4th quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock valued at $136,000 after acquiring an additional 44,939 shares during the period. Byrne Asset Management LLC grew its stake in shares of Lexaria Bioscience by 236.8% in the fourth quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock worth $65,000 after acquiring an additional 74,180 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Lexaria Bioscience during the third quarter valued at approximately $28,000. 13.06% of the stock is currently owned by institutional investors.

About Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.